IBS (O)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/29

encourage image

There's no tags or description

Looks like no tags are added yet.

30 Terms

1
New cards

irritable bowel syndrome (IBS)

functional GI disorder with no specific structural or biochemical alterations

2
New cards

IBS pathophysiology

- visceral hypersensitivity or hyperalgesia
- abnormal GI permeability, motility, secretion, and sensitvity
- postinflammatory IBS
- alteration in gut microbiota
- food allergy or food intolerance
- psychosocial factors

3
New cards

IBS clinical manifestations

- lower abdominal pain
- diarrhea-predominant, constipation-predominant, or alternating diarrhea and constipation
- gas, bloating
- nausea

4
New cards

IBS treatment

- no available cure
- laxative, soluble fiber
- restriction of gluten, FODMAPs
- antidiarrheals
- antispasmodics
- pro-secretory drugs
- visceral analgesics
- low-dose antidepressants
- serotonin agonists/antagonists
- antibiotics

5
New cards

drugs used for IBS-C

- lubiprostone (amitizia)
- linaclotide (linzess)
- tegaserod

6
New cards

lubiprostone (amitizia) administration and uses

- 8 mcg or 24 mcg caps
- taken with food and water

- indicated for tx of chronic idiopathic constipation
- also used for tx of opioid-induced constipation in adults who do not require opioid dosage escalation

7
New cards

lubiprostone MOA and pharmacokinetics

- chloride ion channel activator
> increase chloride-rich intestinal fluid secretion (does not alter Na or K serum levels)
>> easier passage of stool

- metabolized rapidly by reduction and oxidation in stomach and duodenum

<p>- chloride ion channel activator<br>&gt; increase chloride-rich intestinal fluid secretion (does not alter Na or K serum levels)<br>&gt;&gt; easier passage of stool<br><br>- metabolized rapidly by reduction and oxidation in stomach and duodenum</p>
8
New cards

lubiprostone drug interactions

methadone may reduce the activation of chloride channels

9
New cards

lubiprostone contraindications

- in pt with mechanical GI obstructions
- pt with severe diarrhea
- may cause dyspnea within 1 hr of 1st dose
- pregnancy

10
New cards

lubiprostone adverse effects

(most common)
nausea, diarrhea, abdominal pain, abdominal distention, HA, and flatulence

11
New cards

linaclotide (linzess) administration and use

- caps
- taken on empty stomach at least 30 min. before 1st meal of the day

- tx of IBS-C

12
New cards

linaclotide MOA and pharmacokinetics

- agonist of guanylate cyclase-C (GC-C)
> once its active metabolite binds to GC-C, has local effect on luminal surface of the intestinal epithelium
> results in intra- and extracellular increase of cGMP. this elevation stimulates the secretion of chloride and bicarbonate into the intestinal lumen via activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel

- ultimately, helps IBS pt (esp. constipation) as GI transit is accelerated and the release of intestinal fluid is increased

- metabolized to an active and inactive metabolite

<p>- agonist of guanylate cyclase-C (GC-C)<br>&gt; once its active metabolite binds to GC-C, has local effect on luminal surface of the intestinal epithelium<br>&gt; results in intra- and extracellular increase of cGMP. this elevation stimulates the secretion of chloride and bicarbonate into the intestinal lumen via activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel<br><br>- ultimately, helps IBS pt (esp. constipation) as GI transit is accelerated and the release of intestinal fluid is increased<br><br>- metabolized to an active and inactive metabolite</p>
13
New cards

linaclotide contraindications/precautions

- risk of serious dehydration in pediatric pt (< 6 yo) *contraindication*
- avoid use in pt 6 yrs to less than 18 yrs
> safety and effectiveness has not been established in pt <18

- pregnancy category C

14
New cards

linaclotide adverse effects

- diarrhea (16-22%)
- GI: abdominal pain, flatulence, abdominal distension
- respiratory: upper respiratory tract infection,sinusitis

15
New cards

drugs used for IBS-D

- alosterone (lotronex)
- eluxadoline (viberzi)
- rifaximin (xifaxan)
- loperamide (imodium)

16
New cards

alosetron (lotronex) uses

used for tx of:
- diarrhea
- pain
- cramps
- feelings of an urgent need to have bowel movements caused by IBS
> in women who have diarrhea as main symptom and have not been helped by other tx

17
New cards

alosetron MOA

- potent and selective 5-HT3 antagonist
- blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system
> particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing GI contraction and motility, and decreasing GI secretions

<p>- potent and selective 5-HT3 antagonist<br>- blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system<br>&gt; particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing GI contraction and motility, and decreasing GI secretions</p>
18
New cards

alosetron side effects

(more common)
constipation

(rare)
bloody diarrhea, new or worsening stomach pain or discomfort, rectal bleeding

19
New cards

eluxadoline (viberzi) administration and uses

- coated tabs

- tx of IBS-D

20
New cards

eluxadoline MOA

- mixed mu-opioid receptor agonist, delta opioid receptor antagonist, and kappa opioid receptor agonist
> acts locally to reduce abdominal pain and diarrhea in pt with IBS-D without constipating side effects

<p>- mixed mu-opioid receptor agonist, delta opioid receptor antagonist, and kappa opioid receptor agonist<br>&gt; acts locally to reduce abdominal pain and diarrhea in pt with IBS-D without constipating side effects</p>
21
New cards

eluxadoline contraindications

- hypersensitivity to eluxadoline or any component of the formulation
- pt w/o gallbladder; known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction
- history of pancreatitis or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction alcoholism, alcohol abuse, or alcohol addiction, or in pt who drink >3 alcoholic bev per day
- severe hepatic impairment (child-pugh class C); history of chronic or severe constipation or sequelae from constipation
- mechanical GI obstruction (known or suspected)

22
New cards

eluxadoline adverse effects

GI: constipation, nausea, abdominal pain, vomiting, abdominal distention, flatulence

respiratory: upper respiratory tract infection (5%)

23
New cards

rifaximin (xifaxam) uses

hepatic encephalopathy

> reduction in the risk of overt hepatic encephalopathy recurrence in adults


IBS-D

> moderate-severe


travelers' diarrhea

> caused by noninvasive strains of e. coli in adults and pediatric pt > 12 yo

24
New cards

rifaximin MOA

- inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase
> inhibition of bacterial relocation across the gut mucosal epithelium and subsequent release and/or absorption of endotoxin and bacterial metabolites

- modulation of gut - immune signaling

<p>- inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase<br>&gt; inhibition of bacterial relocation across the gut mucosal epithelium and subsequent release and/or absorption of endotoxin and bacterial metabolites<br><br>- modulation of gut - immune signaling</p>
25
New cards

rifaximin drug interactions

cyclosporine (systemic) and P-glycoprotein ihibitors
> may increase serum conc'n of rifaximin

26
New cards

rifaximin adverse effects

(most common) peripheral edema, ascites, dizziness, fatigue, nausea, headache

27
New cards

loperamide (imodium) uses

- tx of IBS-D
- control and symptomatic relief of chronic diarrhea associated with IBS in adults
- acute nonspecific diarrhea in patients > 2 years; to reduce volume of ileostomy discharge

28
New cards

loperamide MOA

- binds to opiate receptor in gut > inhibits release of Ach and prostaglandins > reduction of peristalsis and increasing intestinal transit time

- increases the tone of the anal sphincter > reduction in incontinence and urgency

- acts directly on circular and longitudinal intestinal muscles, through the opiate receptor

- reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity

<p>- binds to opiate receptor in gut &gt; inhibits release of Ach and prostaglandins &gt; reduction of peristalsis and increasing intestinal transit time<br><br>- increases the tone of the anal sphincter &gt; reduction in incontinence and urgency<br><br>- acts directly on circular and longitudinal intestinal muscles, through the opiate receptor<br><br>- reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity</p>
29
New cards

loperamide contraindication

- hypersensitivity to loperamide or any component of the formulation
- abdominal pain w/o diarrhea
- children <2 years; acute dysentery
- acute ulcerative colitis
- bacterial enterocolitis (caused by salmonella, shigella, and campylobacter)
- pseudomembranous colitis associated with broad-spectrum antibiotic use

30
New cards

loperamide adverse effects

(common) constipation, dizziness